Drugs / selonabant
selonabant
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07211607 | Sep 2025 → May 2026 | — | Anebulo Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00734201 | Oct 2008 → Mar 2009 | obesity disorder | Vernalis (R&D) Ltd | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05282797 | Dec 2021 → Aug 2023 | poisoning | Anebulo Pharmaceuticals | Completed | Met primary |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2024-12-23 | Anebulo Pharmaceuticals | Regulatory Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise anebulo.com ↗
FDA acknowledged the unmet need for a treatment for children exposed to cannabis toxicity, and proposed a close, ongoing collaboration to efficiently advance the selonabant program for the pediatric indication |
| 2023-08-21 | Anebulo Pharmaceuticals | Regulatory Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension anebulo.com ↗
The FDA indicated that a single well-controlled study of ANEB-001 in ACI patients presenting to the emergency department combined with a larger THC challenge study in volunteers could potentially provide substantial evidence to support a new drug application. |
| 2023-03-28 | Anebulo Pharmaceuticals | Results Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication anebulo.com ↗
A single 10 mg oral dose of ANEB-001 reduced key symptoms of Accute Cannabinoid Intoxication induced in healthy volunteers by 30 mg challenge dose of oral THC |
| 2023-01-09 | Anebulo Pharmaceuticals | Results Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication anebulo.com ↗
Preliminary data showed ANEB-001 reduced effects of a 30 mg dose of THC |
| 2022-09-26 | Anebulo Pharmaceuticals | Results Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication anebulo.com ↗
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction (the “Company” or “Anebulo”), today announced positive interim data from the first two cohorts of Part B of its ongoing Phase 2 clinical trial evaluating ANEB-001 as a treatment for ACI. |
| 2022-07-05 | Anebulo Pharmaceuticals | Results Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication anebulo.com ↗
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorders (the “Company” or “Anebulo”), today announced positive topline data from Part A of an ongoing Phase 2 clinical trial evaluating the potential of ANEB-001 to treat ACI. |
All press releases naming this drug 11 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | selonabant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07211607 ↗ |
| Known as | ANEB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05282797 ↗ |
| Known as | V24343 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00734201 ↗ |
| Known as | VER-24343 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095165 ↗ |
| Action | Inhibit | “the antagonistic effect of ANEB-001 during a THC challenge” NCT05282797 ↗ |
| Modality | Small molecule | — CHEMBL5095165 ↗ |
| Route | Oral | “Oral” NCT00734201 ↗ |